Pirmenol (CI-845), a new antiarrhythmic drug, was studied for the first time in humans to establish a minimum effective i.v. dose in 10 patients with chronic, stable premature ventricular complexes (PVCs) and to evaluate toxicity and pharmacokinetics. Infusions of 70-150 mg were associated with a 90% or greater reduction in PVCs nine of the 12 times they were administered to six patients. Peak plasma concentrations were 1.0-3.8 Ag/ml at the end of these infusions. At the same time, small but significant increases in diastolic blood pressure (4 mm Hg) and QTc interval (0.01 second) were seen, but both values were within the normal range. Pirmenol was associated with no change in heart rate, systolic blood pressure, PR interval or QRS duration, renal, hepatic or hematologic function, or symptoms. Blood, plasma and free drug concentrations declined biexponentially after cessation of a 150-mg infusion (n = 4), with a terminal half-life of 7-9.4 hours. The therapeutic response, lack of toxicity, and relatively long half-life indicate that pirmenol is a promising antiarrhythmic agent.
THERAPY of cardiac arrhythmias is limited by the small number of antiarrhythmic drugs available and in particular by their side effects.1 2 Pirmenol (CI-845, Parke-Davis) is a new antiarrhythmic agent that has not been evaluated previously in man. It is very effective in dogs with experimental ventricular arrhythmias induced by coronary artery ligation and catecholamine infusions. Therapeutic doses in dogs were associated with a plasma half-life of 4-6 hours; minimal effects on cardiac conduction; a lack of pharmacologic tolerance; a good correlation between dose, plasma level and efficacy; distinct separation of therapeutic and toxic plasma levels; a lack of interference with cardioversion after electrically or chemically induced ventricular fibrillation; and lack of adverse interactions with other antiarrhythmic drugs.3 ' These features suggest that pirmenol might be easier to use than currently available antiarrhythmic drugs.
In this paper we report the initial experience with pirmenol in man. The study was designed to determine the minimally effective i.v. dose of pirmenol and to evaluate toxicity and pharmacokinetics. Methods 
Patients
Ten males, ages 54 ± 6.4 years, with stable premature ventricular complexes (PVCs), sinus rhythm, and no conduction system abnormalities were studied. They had an average of 658 PVCs/hour (range 26-1557 PVCs/hour). Six patients had associated cardiovascular disease, including angina, a previous myocardial infarction and hypertension. None had ever demonstrated New York Heart Association class III or IV congestive heart failure.
Drug Infusion Protocol
Patients were studied in the Clinical Research Unit of Duke University Hospital. All antiarrhythmic drugs were discontinued 4 half-lives before the study. Patients were allowed only water as needed from the preceding midnight through the first four hours of the study period, which began at approximately 8:30 a.m. A modified ECG lead II (bipolar ECG lead with right shoulder negative and cardiac apex positive) was continuously displayed on an oscilloscope and recorded at 25 mm/sec for the entire 4-hour study. The study period was divided into a 1-hour control period, a halfhour infusion period, and a 2½/2-hour observation period. Patients remained supine during all three periods. Pirmenol doses were diluted with normal saline to a volume of 23 ml and delivered at a constant rate by an infusion pump (Harvard Apparatus Co.) during the half-hour infusion. Blood pressure and heart rate were measured every 10 minutes during the control period, every 2 minutes during the infusion, and every 15 minutes during the observation period. At the conclusion of the observation period, patients were fed and allowed to resume normal activities, but the ECG was continuously recorded and displayed for another 4 hours.
A staff cardiologist or a research associate counted by hand the PVCs recorded in each 15-minute period.
The PR interval, QRS duration and QT interval were measured every 30 minutes during the control period, every 10 minutes during the infusion, and every 15 minutes during the observation period.
Blood samples (5 ml) were obtained through an indwelling cannula with a Teflon stilet or separate veni-puncture at 10, 20 and 30 minutes after the start of the infusion. Additional samples were obtained at 0.75, 1, 2, 4, 5, 8, 10, 12 and 24 hours after the start of the infusion of the largest dose administered to each patient. Blood was transferred to glass tubes with a Teflon screw cap containing 10 units of heparin per milliliter of blood. After sampling an aliquot of whole blood, plasma was obtained by centrifugation. Finally, a 24hour urine was collected. All samples were stored at -70°C, which did not affect the assay procedure.
Dose Ranging of Pirmenol
The first six patients received increasing doses of pirmenol. The initial dose in the first patient was 0.5 mg, which was 1/100th of the dose projected to be effective based on preclinical studies. Doses were increased according to the following schedule: doses of 0.5-1.5 mg were followed by three-fold increases; doses of 1.5-15 mg were followed by two-fold increases; and doses greater than 15 mg were followed by 1.5-fold increases. Each of the first six patients received five doses. If no therapeutic effect was observed in one patient, the initial dose given to the next patient was one-third the previous patient's maximum dose. The final four patients received infusions of 50 mg, 100 mg and 150 mg.
Infusions were given every other day. On one day the infusion was normal saline instead of pirmenol. Saline was infused in four patients on day 1, two patients on day 2, two patients on day 4 and two patients on day 5.
Definition of Effective Dose
To determine the responsiveness of PVCs to pirmenol, the 30 minute period with the lowest PVC count during the first hour after the initiation of the pirmenol infusion was compared with the average PVC count per 30 minutes during the 1-hour control period. If a pirmenol dose resulted in a 90% or greater reduction in PVCs, that dose was considered effective.
Clinical Toxicology Screening
The following tests were performed before the initial pirmenol infusion: chest x-ray, ECG, electrolytes, blood urea nitrogen (BUN), creatinine, glucose, complete blood count (CBC), reticulocyte count, bilirubin, alkaline phosphatase, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvate transaminase (SGPT) and total protein. The following tests were performed on each infusion day 2.5 hours after the infusion was discontinued: electrolytes, BUN, creatinine, glucose, CBC, reticulocyte count, protime, bilirubin, alkaline phosphatase, SGOT, SGPT and total protein. The following tests were performed on the day of the initial infusion, at the end of 1 week, and on the day of the final infusion: fluorescent antinuclear antibody, creatinine phosphokinase with isoenzymes, urinalysis and ECG.
No laboratory abnormalities were associated with the infusion of pirmenol.
Assay Methods
Pirmenol concentrations in blood, plasma and urine were measured using high-performance liquid chromatography as previously described., The method is capable of measuring at least 0.1 Ag/ml pirmenol with a coefficient of variation of 7%.
Plasma binding of pirmenol was measured by equilibrium dialysis of 1 ml against Sorensen's phosphate buffer (pH 7.4) at 37°C after spiking with 0.08 ,uCi (4.9 ng) of H3 pirmenol as previously described. 6 Free drug concentration was calculated as the percent of free drug multiplied by the total plasma concentration. The molar ratio of bound to free drug (B/F) was also calculated and related to the concentration of aiacid glycoprotein (AAG) determined by immunodiffusion.7
Pharmacokinetic Calculations
Detailed kinetic analysis of the plasma concentration data on the four patients who received 150 mg of pirmenol was carried out using the NONLIN curvefitting computer program for the data during and after the infusion. A weighing factor of 1/concentration was used and the correlation coefficient for the goodness of fit ranged from 0.97-0.99. Blood pressure, heart rate and conduction intervals were compared using a paired, two-tailed t test. Results
Effect of Pirmenol and Placebo on PVCs
Forty-two infusions were administered to the 10 patients, of which 13 infusions in seven patients 1 ). Although two patients responded to infusions of 20 mg or less, a consistent response was only seen with doses of 70-150 mg. Infusions of 70-150 mg of pirmenol were associated with a greater than 90% reduction in PVCs nine of 12 times they were administered.
The placebo infusion was associated with a 40 i 37% reduction in PVCs.
Effect of Pirmenol on Blood Pressure, Heart Rate and Conduction Intervals Table 1 is a comparison of the changes in several variables between the control period and the time when the peak plasma drug level was reached. Peak plasma drug level occurred 30 minutes after the start of the infusion and was associated with a maximum reduction in PVCs. The only variables that demonstrated a significant increase were the diastolic blood pressure and the QTc interval. The changes, however, were small (4 mm Hg and 0.01 second, respectively) and remained within the normal range. One patient demonstrated prolongation of the QRS complex following 150 mg of pirmenol. The QRS prolongation occurred in association with a blood level of 3.8 ,ug/ml, the highest level observed in any of the patients.
Plasma Concentrations of Pirmenol
Peak plasma pirmenol concentration exceeded Ag/ml after all of the doses of 70 mg or greater. The highest concentration was 3.8 ug/ml ( fig. 2 ). In the four patients who received the 150-mg dose, the arrhythmia was abolished for 2-4 hours and plasma concentrations of 1.4, 1.1, 1.0, and 0.8 gg/ml were noted at the return of the arrhythmia. Plasma levels and PVC counts from patient 8 are shown in figure 3 . The arrhythmia began to reappear when the plasma level was 1 gg/ml. Although two patients responded at lower peak concentrations, these data suggest a minimal effective plasma concentration of about I Ug/ml. PATIENT FIGURE 1. The dose-ranging protocol (see Methods) to determine the minimum effective dose of pirmenol. Solid circles indicate more than 90% reduction in premature ventricular complexes; open circles indicate less than 90% reduction.
Detailed Pharmacokinetics
Blood, plasma and free pirmenol concentrations were measured at various times up to 24 hours in the four patients who received the 150-mg infusion over 30 minutes. In all four, plasma concentrations were greater than those in blood, which exceeded free drug concentrations. All concentrations fell biexponentially after cessation of the infusion. The data from one of the patients are illustrated in figure 4 and the 0.43 ± 0.03 0.43 ± 0.06 0.42 ± 0.04 0.43 ± 0.04* The placebo values were obtained in all 10 patients. The effective dose values were obtained using the 13 pirmenol infusions that were associated with a greater than 90% reduction in premature ventricular complexes. The infusion measurements were taken 30 minutes after the start of the infusion when the plasma drug level was the highest.
*Different from effective dose control (p < 0.05). Abbreviations: SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; PR = PR interval; QRS = QRS duration; QTc = corrected QT interval. I   I  I   2  4  6  8 10 TIME, HOURS FIGURE 4. Plasma, blood, and free pirmenol concentrations in a patient given a 150-mg infusion over 30 minutes. The inset represents the two-compartment model to which the data in table 2 were fitted. See text for abbreviations. the end of the infusion were linearly related to the dose ( fig. 5 ).
The Effects of Body Weight
Peak concentrations at the end of the infusion were previously proved to correlate with the dose infused in Abbreviations: a = initial phase rate constant; /3 = terminal phase rate constant; Vc = volume of distribution of central compartment; K = microscopic rate constant (see fig. 4 ); TV2 a = half-life of initial phase; Tj /3 = half-life of terminal phase; B/P = blood-plasma drug concentration ratio. nine subjects (r = 0.87, p < 0.01). We also examined whether peak concentration was related to body weight by calculating the concentration per milligram of the highest dose infused. No correlation was found (r = 0.02). The AUC for pirmenol did not obviously relate to the subject's weight (table 2) . Plasma Drug Binding
In six of the patients, data on plasma binding were available and the amount of free drug ranged from 9.1-17.4%. There was also a strong correlation between the binding ratio (B/F) and the concentration of acid glyroprotein (r = 0.957; p < 0.001) ( fig.   6 ). The fact that this plot has an intercept of B/F = 1.64 when there is no AAG present indicates that pirmenol is 62% bound to another constituent of plasma.
Discussion This initial experience in 10 patients suggests that pirmenol is a safe and effective antiarrhythmic agent. We chose 90% suppression of PVCs as indicative of effectiveness on the basis of the experience of Winkle8 and Morganroth et al., 9 who suggested that this degree of suppression or greater was required to exclude spontaneous variability and placebo reactions. Winkle's data suggest that 100% suppression is necessary if a half-hour control period is compared to a 1-hour response period. We chose not to use 100% suppression in this study because our control period was 1 hour, and because pirmenol had not previously been administered to patients. Demanding 100% suppression to demonstrate drug effectiveness would increase the risk of toxicity.
Pirmenol was free of side effects or toxicity over the range of doses studied. One patient did have prolonged QRS duration, which increased from 0.08 second to 0.10 second, when the peak plasma concentration was 3.8 ,g/ml. This was the highest plasma concentration observed during the study and suggests that pirmenol may slow conduction at high plasma levels. In addition, small group increases were observed in diastolic blood pressure (4 mm Hg) and QTc (0.01 second). The extensive laboratory evaluation failed to detect any abnormalities associated with pirmenol administration. The effective dose of pirmenol varied widely among our patients. Although two patients apparently responded to infusions of 9 and 20 mg, a consistent response was only seen when 70-150 mg was infused. The effective doses were associated with plasma pirmenol concentrations of 1-3.8 ,gg/ml at the end of the infusion. The fact that the arrhythmia returned at concentrations of 0.8-1 ug/ml suggests that 1 ,g/ml represents the average minimal therapeutic concentration, a value that is consistent with the animal data. 4 Although pharmacokinetic data obtained during early dose-ranging studies are limited by small numbers, a considerable amount of important information can be obtained concerning the disposition of the compound. In the present study, data were obtained in four subjects who received three doses of pirmenol over the putative therapeutic range. The fact that peak plasma concentrations at the end of a 30-minute infusion increased appropriately with the dose suggests that the kinetics of pirmenol are generally linear and that neither elimination nor distribution are dosedependent. In addition, peak concentration in nine patients was related to the dose administered, but not to body weight.
The kinetics of the drug are best described by a twocompartment model showing a very rapid early (a) phase with a half-life of about 10 minutes, followed by a much more prolonged terminal (,) phase half-life of 7-9 hours. This suggests that the required dosage interval during chronic administration should be longer than needed with traditional antiarrhythmics, such as procainamide and quinidine, which have shorter halflives.
Pirmenol is highly bound to plasma proteins (83-90%), which accounts for the low blood/plasma drug concentration ratio of about 0.65 and suggests that free drug equilibrates with the cellular elements in the blood. The binding ratio for pirmenol correlated well with the concentration of the acute phase reactant, AAG. This is also true of some other antiarrhythmic drugs, including lidocaine6 and propranolol,'0 and suggests the plasma binding of pirmenol may also be enhanced after myocardial infarction, as it is with the other drugs.", 12 The present data also indicate that in the absence of AAG, pirmenol would be about 62% bound to another plasma protein, presumably albumin. The volumes of distribution of the drug are in the intermediate range, but if these are calculated in terms of free drug, they far exceed total body water, indicating considerable concentration in body tissues.
The whole blood clearance of pirmenol is relatively low (200 ml/min) and is shared equally by the renal and nonrenal routes of elimination. The renal clearance of total drug is relatively low (100 ml/min). However, when this is calculated in terms of free drug, the value (400-500 ml/min) far exceeds glomerular filtration rate and indicates active or pH-dependent secretion by the kidney. The site of nonrenal elimination has not been identified, but assuming that it is by hepatic metabolism, the low clearance value compared to liver blood flow suggests that there will be little or no pre-systemic or "first-pass" effect.
Reder and associates's demonstrated that pirmenol had effects similar to local anesthetic-type antiarrhythmic agents. Using an isolated dog Purkinje fiber preparation, they concluded that pirmenol reduced the rate of rise of phase 4 spontaneous depolarization, and the maximum rate of rise of phase 0, accelerated early repolarization and prolonged the action potential duration. These effects were independent of the potassium concentration. This final property is unique to pirmenol in that other antiarrhythmic drugs demonstrate alterations in their effect when the potassium concentration is varied." 146 Reder et al. ' 3 also noted that the effects of pirmenol were concentration-dependent and were consistent with a depressant action on atrioventricular conduction. They found a significant increase in the PR interval with a tendency for pirmenol to increase the QRS duration and QTc interval.
Pirmenol appears to be effective and safe after 30minute i.v. infusions of 70-150 mg. Pirmenol has a favorable pharmacokinetic profile with a half-life of 7-9 hours. 15. Singh BN, Vaughn-Williams EM: Effect of altering potassium concentrations on the action of lidocaine and diphenyl-hydantoin on rabbit atrial and ventricular muscle. Circ Res 29: 286, 1971 16. Danilo P, Hordof AJ, Rosen MR: Effects of disopyramide on electrophysiologic properties of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 201: 701, 1977 Sequelae of the Initial Attack of Acute Rheumatic Fever in Children from North India patients had rheumatic heart disease. Mitral insufficiency, the most common valvular lesion, appeared in 91% of the patients, whereas mitral stenosis developed in only 18%. Initial carditis, congestive heart failure, cardiomegaly or moderate-to-severe mitral insufficiency significantly increased the risk of rheumatic heart disease (p < 0.001). The recurrence rate of acute rheumatic fever in children who received continuous prophylaxis was 0.006 per patient-year. Most recurrences (92%) mimicked the first attack and produced further cardiac damage in five patients with carditis and in one patient with chorea. Cardiac status during the first attack of rheumatic fever and the continuity of prophylaxis were the major determinants of outcome. Statistical comparisons disclosed that with continuous prophylaxis, the prevalence rate, evolution and clinical spectrum of the sequelae of acute rheumatic fever in children from India do not differ significantly from those in the West. ACUTE rheumatic fever (ARF) is generally believed to be more severe in India and neighboring countries than it is in the West.' This opinion is controversial, primarily because of the divergent reports of the disease from the Indian subcontinent. For example, De Silva2 and Padmavati3 emphasized the paucity of severe manifestations of ARF in children from Sri Lanka (Ceylon) and New Delhi, respectively. In contrast, Roy et al.4 reported a much higher incidence of carditis and congestive heart failure, and concluded that ARF occurred in a more severe form in North India than in the West. High frequencies of cardiac involvement have been reported from South India,5 Iran,6 Pakistan7 and Egypt."
All but one of these studies, however, were retrospective, and no clear distinction was made in the analysis of first compared with recurrent attacks or with regard to the frequency of major manifestations of the disease.9 When we undertook a prospective study in a general pediatric outpatient clinic that served a large section of New Delhi and adjacent states, and admitted all patients with a first attack of ARF, the relative frequencies of major manifestations of the disease-were very similar to the spectrum prevalent in the West.'0 Our findings then raised the question as to whether the sequelae of the first attack of ARF in children from India were truly different from those reported elsewhere. The purposes of this article are to report results from a prospective 5-year follow-up of these patients, with emphasis on the sequelae of ARF and factors that may contribute to residual rheumatic heart disease (RHD), and to compare our findings with those from the West.
Materials and Methods Patient Population
The original study comprised 102 children who had a first attack of ARF. The description of this patient group, the results of the initial evaluation and the diagnostic criteria for ARF and carditis that were used, have been reported elsewhere.'0'3 Of this group, 85 children, 52 boys and 33 girls, 5-12 years old (mean 8.7 years), returned to the cardiac clinic and entered our 5-year prospective study.
Management of ARF (Initial Attack)
Soon after admission to the original study, each patient received a single intramuscular injection of
